All relevant data are within the paper, its Supporting Information files, and from figshare at <https://doi.org/10.6084/m9.figshare.10252772.v1>.

Introduction {#sec001}
============

Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is a member of the UDP-glucuronosyltransferase 1A enzyme family that is mainly localized in the smooth endoplasmic reticulum in the liver and other tissues \[[@pone.0225244.ref001]\]. UGT1A1 plays an essential role in the metabolism of about 80 chemical substances including bilirubin and CPT-11 (irinotecan), an anticancer agent \[[@pone.0225244.ref002], [@pone.0225244.ref003]\]. Locuson and Tracy \[[@pone.0225244.ref004]\] reported on a binding model of UGT1A1 with a coenzyme, UDP-glucuronic acid (UDPGA), whose binding site included the amino acids S38, H173, G308, L355, S375, H376, and G377. In our previous research based on their report, we showed that conjugation proceeded when the hydroxyl residue of bilirubin was oriented toward UDPGA \[[@pone.0225244.ref005]\].

Mutations of the *UGT1A1* gene have been found in hereditary diseases, such as hyperbilirubinemia, Crigler-Najjar syndrome, and Gilbert syndrome, and at least 70 mutations of this gene have been reported \[[@pone.0225244.ref006]\]. An adverse reaction to the drug CPT-11 is well known to be associated with mutant *UGT1A1* \[[@pone.0225244.ref007]\]. Major mutations of *UGT1A1*, especially the *UGT1A1\*6* and *UGT1A1\*28* mutations, are well known to reduce conjugation capacity. The former mutation causes the loss of function in conjugation capacity because of the amino acid substitution of G71R \[[@pone.0225244.ref008]\], and the latter induces a quantitative reduction in *UGT1A1* gene expression with an increase in the TA repeat from 6 to 7 of the promoter region \[[@pone.0225244.ref009], [@pone.0225244.ref010]\]. CPT-11 is converted to SN-38, an active metabolite, and is then metabolized to become a water-soluble form via glucuronidation of the UGT1A1 enzyme \[[@pone.0225244.ref011]\]. The risk for CPT-11 toxicity increases with these genetic variants. Today, a genetic test for *UGT1A1*, especially the *UGT1A1\*6* and *UGT1A1\*28* mutations, is performed before treatment with CPT-11, because use of CPT-11 carries a high risk of adverse effects such as severe neutropenia and diarrhea \[[@pone.0225244.ref012]\]. In addition, sequencing technology can determine the new amino acid substitutions in UGT1A1, but the glucuronidation capacities of these new mutant UGT1A1s for any substrate, such as SN-38 are usually unknown.

Our molecular simulation analysis that was based on structural biology recently became a powerful tool for studying the biochemical process \[[@pone.0225244.ref013]--[@pone.0225244.ref018]\]. Previously, our *in silico* study of the conjugation process showed that this enzymatic reaction was controlled by the direction of the vicinal hydroxyl group in the substrate \[[@pone.0225244.ref005]\]. In addition, mathematical models are used for research on biological processes, such as those in drug-drug interactions (DDIs) and drug metabolism \[[@pone.0225244.ref019], [@pone.0225244.ref020]\].

For our research reported here, we revised our previous molecular simulation analyses, which led to a mathematical model for the conjugation process in order to predict the conjugation capacity for substrates such as bilirubin and SN-38. Coenzyme or substrate docking after structural optimization with water and lipid bilayers was performed to mimic the cellular environment instead of the *in vacuo* environment that we had used in our previous research. We subsequently developed a mathematical model that we derived from the results from *in vitro* and *in silico* analyses. Then we demonstrate here that our mathematical model using the docking results for a specific number of UDPGA-oriented hydroxyl residues of substrates can predict the conjugation capacities of mutant UGT1A1s.

Materials and methods {#sec002}
=====================

Construction of the 3D structures of UGT1A1 mutants {#sec003}
---------------------------------------------------

The 3D structure of wild-type UGT1A1 was obtained from ModBase \[[@pone.0225244.ref021]\] (Model ID: 2420a568b0f3d1b1fe06fc34a94eee40). We then added hydrogen atoms to the model structure via PyMOL software \[[@pone.0225244.ref022]\], after which we prepared structures of UGT1A1 mutants: G71R, F83L, P229L, P229Q, L233R, I294T, I322V, R336L, H376R, P387S, N400D, and W461R, whose PMIDs in the Protein Model Database \[[@pone.0225244.ref023]\] are PM0082268, PM0082269, PM0082278, PM0082271, PM0082279, PM0082275, PM0082270, PM0082272, PM0082273, PM0082274, PM0082276, and PM0082277, respectively. We prepared these structures by using molecular operating environment (MOE) software (Chemical Computing Group Inc., Montreal, QC, Canada). Each model structure of the wild-type UGT1A1 and mutant UGT1A1s was embedded in the lipid bilayer using visual molecular dynamics (VMD) software \[[@pone.0225244.ref024]\]. The location of the bilayer was determined according to a previous report \[[@pone.0225244.ref025]\]. The transferable intermolecular potential with three points (TIP3P) water model \[[@pone.0225244.ref026]\] was used for structural optimization of UGT1A1 with water. The minimal distance of a protein atom to the edge of the rectangular water box was 14 Å.

The structural data were then subjected to structural optimization with the AMBER10:EHT force field according to our previous study \[[@pone.0225244.ref027]\] with slight modifications. We performed energy minimization by means of the molecular mechanics (MM) function of the MOE software by using the steepest descent method until the root mean square gradient was 0.01 kcal/mol/Å. Then, we used NAMD software to perform molecular dynamics (MD) simulations \[[@pone.0225244.ref028]\]. The water-protein-bilayer system was gradually heated from 0 K to 310 K during 250 ps. After the heating process, a 10,000-ps production run was performed with the NPT ensemble in a unit of 2 fs. The temperature and pressure of the system were maintained by using the Berendsen coupling algorithm \[[@pone.0225244.ref029]\]. The SHAKE algorithm \[[@pone.0225244.ref030]\] was used to constrain water bond geometries. The root mean square deviation (RMSD) from the 10,000-ps molecular dynamics trajectory was analyzed by using VMD ([S1A Fig](#pone.0225244.s001){ref-type="supplementary-material"}). Each trajectory was stable after 8000 ps. The quality of each 3D UGT1A1 structure was ascertained via the PROCHECK program \[[@pone.0225244.ref031]\], which yielded 1.8% or less in the disallowed regions of the Ramachandran plot ([S1B and S1C Fig](#pone.0225244.s001){ref-type="supplementary-material"}). This provided an insight into the correctness of the modeled structures in terms of PROCHECK as reported previously \[[@pone.0225244.ref032]\]. Each UGT1A1 molecule in the last frame ([S2 Fig](#pone.0225244.s002){ref-type="supplementary-material"}) was used for the docking analysis.

Docking analysis of UGT1A1 with UDPGA {#sec004}
-------------------------------------

The docking of UDPGA and each UGT1A1 mutant was analyzed by means of AutoDock4 \[[@pone.0225244.ref033]\] according to our previous research \[[@pone.0225244.ref005]\] with slight modifications. The docking site was defined by using the AutoGrid program as a box within 3.8 Å of the amino acids that reportedly interact with UDPGA \[[@pone.0225244.ref004]\]. This value was determined by means of the sum of the H bond distance (3.2 Å) \[[@pone.0225244.ref034]\] and the error of the AutoDock (0.6 Å), which we found in our preliminary analysis ([S1 Text](#pone.0225244.s008){ref-type="supplementary-material"}, [S1 Table](#pone.0225244.s005){ref-type="supplementary-material"}). Grids were searched via the Lamarckian genetic algorithm. All other parameters were defined by default settings. All hydrogen atoms were added and water molecules were removed. One hundred different docking runs were performed for each UGT1A1-UDPGA pair.

Docking for each UGT1A1 molecule and the coenzyme UDPGA was performed in the binding mode similar (wild-type) or neighboring (mutants) to that in previous research \[[@pone.0225244.ref004]\], which are comprised of amino acids S38, H173, G308, L355, S375, H376, G377, and was defined as the correct binding mode.

Analysis of UGT1A1 docking with acetaminophen (AAP) and 17β-estradiol (E2) {#sec005}
--------------------------------------------------------------------------

We simulated AAP and E2 docking to each UGT1A1 mutant by means of the AutoDock4 program. The 3D structural data of the substrates were obtained from ChemIDplus (registry numbers: 103-90-2 for AAP, 50-28-2 for E2).

The docking site for each of the correctly bound complexes of UGT1A1 and UDPGA was located in front of the bound UDPGA and was sufficiently large to cover the binding site for all substrates that we used in this study. The far boundary of the docking site was defined as 0.5 Å back of the center of the C-O bond between glucuronic acid and UDP of UDPGA.

We performed 100 docking runs for each UGT1A1-substrate pair. We analyzed the number of docking poses with a hydroxyl group oriented toward the coenzyme, that is, the hydroxyl group of the substrate was located within 3.8 Å of the center of the C-O bond between glucuronic acid and UDP of UDPGA, which we had identified as the hydroxyl orientation and the correct binding mode in our previous report \[[@pone.0225244.ref005]\]. [Fig 1A, 1B, 1C and 1D](#pone.0225244.g001){ref-type="fig"} show representative docking results of hydroxyl orientations and other orientations that cannot function in the conjugation reaction. [Fig 1E](#pone.0225244.g001){ref-type="fig"} shows the field of the conjugation process in wild-type but the field completely lacks in R336L mutant ([Fig 1F](#pone.0225244.g001){ref-type="fig"}).

![The complexes of UGT1A1 with coenzyme and substrates.\
Pairs of UDPGA and substrates for wild-type UGT1A1 are as follows: A: UDPGA and AAP; B: UDPGA and E2; C: UDPGA and bilirubin; and D: UDPGA and SN-38. Top panels in each pair show the binding modes that can function in the conjugation reaction: the hydroxyl group of the substrate (red circle) is oriented toward UDPGA, which we call hydroxyl orientations; bottom panels show the binding modes that cannot function in the conjugation reaction. The UGT1A1 structures are shown as ribbon representations. UDPGA and substrates are shown as orange and blue sticks, respectively. (E and F) Cross-sectional images of wild-type UGT1A1 and R336L UGT1A1 structures highlighting the location of the glucuronidation and the amino acids of the coenzyme binding. The field of the conjugation process was disrupted in R336L.](pone.0225244.g001){#pone.0225244.g001}

*In vitro* analysis of glucuronidation for AAP and E2 {#sec006}
-----------------------------------------------------

*In vitro* conjugation capacities of wild-type UGT1A1 and mutant UGT1A1s were analyzed as described previously \[[@pone.0225244.ref035]\] with a slight modification. Human UGT1A1 cDNA was obtained from a human liver cDNA library by PCR amplification and was inserted into a pENTR/D-TOPO vector. Mutations were introduced by using a site-directed mutagenesis method with substitutions at nucleotide positions c.211G\>A (p.G71R), c.247T\>C (p.F83L), c.964A\>G (p.I322V), c.1007G\>T (p.R336L), c.1127A\>G (p.H376R), and c.1159C\>T (p.P387S).

Each wild-type and mutant UGT1A1 sequence was inserted into the expression vector pcDNA-DEST40 Gateway by recombination. The UGT1A1 expression vectors, together with a luciferase reporter vector (pGL3 vector) as an indicator of transfection efficiency, were transfected into COS-7 cells by using Lipofectamine 2000, according to the manufacturer's instructions. The cells were harvested at 48 h after transfection and then homogenized with 70 μL of 0.1 M Tris--HCl (pH 7.5). The cell homogenates were used for UGT1A1 activity and luciferase assays. Luciferase activity was measured with a TD-20/20 luminometer (Promega, Madison, WI, USA) and was used to normalize enzyme activities of the UGT1A1 clones.

Glucuronidation of AAP and E2 was analyzed with the UGT Reaction Mix containing UDPGA (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), according to the manufacturer's instructions. Briefly, a 99-μL sample of the reaction mixture containing 20 μL of Solution A, 8 μL of Solution B, 1 μL of 20 mM AAP or 0.25 mM E2 in ethanol, and 70 μL of cell homogenates was incubated at 37°C for 2 h. The reaction was terminated by adding 25 μL of acetonitrile for AAP or 25 μL of 94% acetonitrile/6% glacial acetic acid for E2.

After the reaction termination, 5 μL of 1mM *p*-nitrophenyl β-[d]{.smallcaps}-glucuronide (PNPG) or 1 μL of 300 μM ethynylestradiol (EE2) in ethanol was added to the reaction mixture as an internal standard. Then, the reaction mixture was centrifuged and the supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine the amount of AAP glucuronide (AAPG) or E2 glucuronide (E2G).

Chromatography was performed with a Shimadzu LC10AD system (Shimadzu, Kyoto, Japan) with a mobile phase consisting of 40% acetonitrile and 25 mM ammonium acetate at a flow rate of 0.3 mL/min for AAP, or 70% methanol, 4.5% of acetonitrile, and 0.15 mM perchloric acid at a flow rate of 0.2 mL/min for E2. The column temperature was maintained at 45°C. A 15-μL aliquot of each sample was injected onto a Shim-pack CLC-ODS column (4.6 mm I.D. × 15 cm; Shimadzu).

An API-3000TM LC-MS/MS system (Applied Biosystems/MDS SCIEX, Toronto, Canada) was operated with an electrospray ionization source (ESI; TurboIonSpray interface) coupled with the LC system described above. MS scanning was operated in a negative ion mode. Analyst 1.3.1 software was used for equipment control, data acquisition, and analysis. The glucuronide peaks were detected at *m/z* 326.1/150.0 \[precursor ion (Q1)/product ion (Q3)\] for AAPG and *m/z* 447.1/271.1 (Q1/Q3) for E2G. These glucuronide peaks were confirmed because their retention times were the same as those of commercially available authentic standards. With regard to the sensitivity of all assays, the minimal level of detection was 3 ng/assay. Experiments were repeated five times; the coefficient of variation was less than 12%. [S3 Fig](#pone.0225244.s003){ref-type="supplementary-material"} shows representative LC-MS/MS chromatograms.

Mathematical model for conjugation capacity of UGT1A1 {#sec007}
-----------------------------------------------------

To establish a mathematical model for glucuronidation by UGT1A1, the enzymatic reaction of UGT1A1 was described by an equation as follows: we first compared *in vitro* conjugation capacity with the results of docking simulation analyses; we then derived an equation that calculated *in vitro* conjugation capacity by using the docking results that showed a strong correlation with *in vitro* conjugation capacity. Different efficiencies of glucuronidation with individual substrates were incorporated into the equation by using the docking results for wild-type UGT1A1.

Verification of the mathematical model by cross-validation {#sec008}
----------------------------------------------------------

To verify the mathematical model, we used leave-one-out cross-validation with AAP and E2 as substrates as follows: We removed one of the UGT1A1 mutants, determined the constants of the mathematical model by using the rest of the mutants, and then performed calculations to predict the *in silico* conjugation capacity for the excluded mutant. Finally, we calculated Pearson's correlation coefficient for the *in silico* and the *in vitro* conjugation capacities.

Validation of the experimental procedure: Prediction of conjugation capacity of bilirubin and SN-38 {#sec009}
---------------------------------------------------------------------------------------------------

To examine the validity of this experimental procedure, we prepared structures of the mutants P229Q, I294T, N400D, W461R, P229L, and L233R for only bilirubin and/or SN-38. The 3D structures of bilirubin and SN-38 were obtained from ChemIDPlus (registry numbers: bilirubin, 635-65-4; SN-38, 86639-52-3) for docking analyses. The docking analyses were performed for the pairs of substrates and UGT1A1 mutants whose *in vitro* conjugation capacities were reported. To use our mathematical model, docking analyses of bilirubin with UGT1A1s (wild-type, G71R, F83L, P229Q, I294T, N400D, W461R) and SN-38 with UGT1A1s (wild-type, G71R, P229L, P229Q, L233R) were performed in the same manner as those for AAP and E2. The *in silico* conjugation capacity of each substrate was calculated by means of our mathematical model and then compared with the reported *in vitro* conjugation capacity. Finally, a correlation plot was analyzed for verification of the mathematical model by using all prediction results for *in silico* and *in vitro* data.

Statistical analysis {#sec010}
--------------------

Statistical analyses were performed with R software (R Core Team 2015). Data are presented as means ± SD. A *P* value of \<0.05 was regarded as statistically significant.

Results {#sec011}
=======

Correlation between the results of docking simulation and *in vitro* conjugation capacity {#sec012}
-----------------------------------------------------------------------------------------

To evaluate the results of molecular simulation analyses for the mathematical model for glucuronidation by UGT1A1, we compared the *in vitro* conjugation capacity of UGT1A1 against AAP and E2 with the results of docking simulation analysis ([Fig 2](#pone.0225244.g002){ref-type="fig"}, [S2 Table](#pone.0225244.s006){ref-type="supplementary-material"}). A significant correlation existed between the number of hydroxyl orientations of substrate and *in vitro* conjugation capacity, as we reported previously \[[@pone.0225244.ref005]\] ([Table 1](#pone.0225244.t001){ref-type="table"}).

![Comparison between docking results and *in vitro* conjugation capacities of wild-type UGT1A1 and UGT1A1 mutants for AAP and E2.\
(A) The number of correct binding modes of UDPGA per 100 separate docking runs. (B and C) The number of hydroxyl orientations of substrate per 100 separate docking runs. [S2 Table](#pone.0225244.s006){ref-type="supplementary-material"} provides raw data for docking results for panels A, B, C, and D. (D and E) *In vitro* conjugation capacity. ND, not detected.](pone.0225244.g002){#pone.0225244.g002}
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###### Correlation of docking simulation results with *in vitro* conjugation capacity of UGT1A1.

![](pone.0225244.t001){#pone.0225244.t001g}

  Substrate   Correct binding mode of UDPGA   Hydroxyl orientation of substrate           
  ----------- ------------------------------- ----------------------------------- ------- ------------------
  AAP         \- 0.189                        0.7195, \>0.05                      0.954   0.0032, \<0.01
  E2          0.114                           0.8298, \>0.05                      0.994   0.00005, \<0.001

A correlation also existed between the number of hydroxyl orientations of the substrate and *in vitro* conjugation capacity for the other UGT1A isoforms, UGT1A10 and UGT1A7 ([S2 Text](#pone.0225244.s009){ref-type="supplementary-material"}, [S4 Fig](#pone.0225244.s004){ref-type="supplementary-material"}). However, no significant correlation was found between the binding mode of UDPGA and *in vitro* conjugation capacity. These results suggest that the hydroxyl orientations of the substrate can be used to derive the mathematical model for glucuronidation by UGT1A1.

Derivation of a mathematical model for estimating the conjugation capacity of UGT1A1 {#sec013}
------------------------------------------------------------------------------------

A mathematical model to predict the conjugation capacity of UGT1A1 was derived as described below. Glucuronidation involves the following steps: (i) binding of coenzyme UDPGA to UGT1A1; (ii) binding of substrate to the UGT1A1-UDPGA complex; (iii) conjugation of glucuronic acid with the substrate \[[@pone.0225244.ref036]\]. The conjugation capacity of UGT1A1 (*P*~*C*~) can be represented as the product of (i) and (ii): $$P_{c} = C \times S$$ where *C* is the contribution of (i) to conjugation capacity and *S* is the contribution of (ii) to conjugation capacity.

The difference in the docking results for each substrate with wild-type UGT1A1 ([Fig 2B and 2C](#pone.0225244.g002){ref-type="fig"}) is represented by the substrate-specific constant σ, and ε represents the *in vivo* environment of the enzymatic reaction:: $$P_{c} = \sigma \times C \times S + \varepsilon$$ The value of ε is set to 0 to predict *in vitro* conjugation capacity.

Because no correlation exists between the correct binding mode of UDPGA and *in vitro* conjugation capacity ([Table 1](#pone.0225244.t001){ref-type="table"}), *C* is replaced with 1: $$P_{c} = \sigma \times S + \varepsilon$$ *S* is defined as $$S = \left( \frac{S_{DH}}{S_{DT}} \right)^{\beta_{l}}\ where\ \beta_{l} = \frac{S_{DT}}{S_{DH,wild}}$$ where *S*~*DT*~ is the total number of substrate docking and *S*~*DH*~ is the number of hydroxyl orientations of the substrate \[[@pone.0225244.ref005]\].

Because the enzymatic reaction follows a sigmoid curve \[[@pone.0225244.ref037]\], *S* can be defined by using a sigmoid function: $$S = \left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH}}{S_{DT}} - \mu_{l}})}} \right)^{\beta_{l}}\ where\ \beta_{l} = \frac{S_{DT}}{S_{DH,wild}}$$ In addition, we define a variable κ to represent TA repeat polymorphism (UGT1A1\*28) in the promoter region that is based on the relative values to wild-type/wild-type for each genotype according to the *V*~max~ values in the previous report: wild-type/wild-type, 16.2 nmol/min/mg; wild-type/\*28, 12.0 nmol/min/mg; \*28/\*28, 3.4 nmol/min/mg \[[@pone.0225244.ref010]\]: $$P_{c} = \sigma \times \kappa \times \left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH}}{S_{DT}} - \mu_{l}})}} \right)^{\beta_{l}} + \varepsilon$$ $$where\ \kappa = \begin{cases}
{\ {1.0\quad{wild}‐{type}/{wild}‐{type}}} & \\
{0.74\qquad{{wild}‐{type}/*28}} & \\
{0.21\mspace{54mu}{*28/*28}} & \\
\end{cases}$$

Constant values σ, *γ*~l~, μ~l~, and ε were estimated by minimizing the sum of squared error between *in silico* conjugation capacity *P*~*C*~ and *in vitro* conjugation capacity *V*~*c*~: $$\left( {\sigma,\gamma_{l},\mu_{l},\varepsilon} \right) = argmin\left\{ {\sum_{M}\left( {P_{c} - V_{c}} \right)^{2}} \right\}$$ where set *M* represents the UGT1A1 mutants whose *in vitro* conjugation capacities are known and correct binding modes of UDPGA were obtained by docking analysis.

The relative conjugation capacity of mutant UGT1A1 (percentage of wild-type) is defined by following equation: $$P_{c} = \frac{\sigma \times \kappa \times \left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH}}{S_{DT}} - \mu_{l}})}} \right)^{\beta_{l}} + \varepsilon}{\sigma \times \left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH,wild}}{S_{DT}} - \mu_{l}})}} \right)^{\beta_{l}} + \varepsilon} \times 100$$

In the case of ε *=* 0, Eq ([8](#pone.0225244.e009){ref-type="disp-formula"}) is represented by Eq ([9](#pone.0225244.e010){ref-type="disp-formula"}): $$P_{c} = \frac{{\kappa \times \left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH}}{S_{DT}} - \mu_{l}})}} \right)}^{\beta_{l}}}{\left( \frac{1}{1 + e^{- \gamma_{l}({\frac{S_{DH,wild}}{S_{DT}} - \mu_{l}})}} \right)^{\beta_{l}}} \times 100$$

[S2 Table](#pone.0225244.s006){ref-type="supplementary-material"} shows the variables and constants of the mathematical model for the docking results for each UGT1A1 variant.

Validation of the mathematical model {#sec014}
------------------------------------

To verify our mathematical model, we validated Eq ([9](#pone.0225244.e010){ref-type="disp-formula"}) by using leave-one-out cross-validation and leaving out one mutant per fold. We calculated the *in silico* conjugation capacity of AAP and E2 by using the docking results ([S2 Table](#pone.0225244.s006){ref-type="supplementary-material"}), and we then compared the result with *in vitro* conjugation capacity ([Fig 3A and 3B](#pone.0225244.g003){ref-type="fig"}). We found a significant correlation between *in silico* conjugation capacity and *in vitro* conjugation capacity ([Fig 3C](#pone.0225244.g003){ref-type="fig"}). On the basis of these results, we confirmed our mathematical model to be useful for predicting the conjugation capacity of mutant UGT1A1.

![Cross-validation of *in silico* conjugation capacity of UGT1A1 with *in vitro* conjugation capacity.\
(A) *In silico* conjugation capacities (gray bars) of AAP were compared with *in vitro* conjugation capacities (black bars). (B) *In silico* and *in vitro* conjugation capacities of E2 were compared, as done for AAP. (C) Pearson\'s correlation coefficient was used to assess cross-validation. ND, not detected.](pone.0225244.g003){#pone.0225244.g003}

Validation of the experimental procedure: Prediction of the conjugation capacity of bilirubin and SN-38 {#sec015}
-------------------------------------------------------------------------------------------------------

We performed the docking analyses of UGT1A1 with bilirubin and SN-38 in the same manner as those for AAP and E2 ([S2 Table](#pone.0225244.s006){ref-type="supplementary-material"}). The *in silico* conjugation capacities were calculated by inserting the docking results into Eq ([9](#pone.0225244.e010){ref-type="disp-formula"}), and we then compared these results with the reported *in vitro* conjugation capacities \[[@pone.0225244.ref008], [@pone.0225244.ref038]--[@pone.0225244.ref041]\] (Figs [4](#pone.0225244.g004){ref-type="fig"}, [5A and 5B](#pone.0225244.g005){ref-type="fig"}). We found significant correlations between *in silico* and *in vitro* conjugation capacities ([Fig 5C](#pone.0225244.g005){ref-type="fig"}). These results indicate that our method for the prediction of conjugation capacity is valid in the tested cases of bilirubin and SN-38. [Fig 6](#pone.0225244.g006){ref-type="fig"} indicates that our experimental procedure is effective for predicting the conjugation capacity, because all *in silico* results and *in vitro* results were significantly correlated.

![Comparison between docking results and *in vitro* conjugation capacities of wild-type UGT1A1 and UGT1A1 mutants for bilirubin and SN-38.\
(A) The number of correct binding modes of UDPGA per 100 separate docking runs. (B and C) The number of hydroxyl orientations of substrate per 100 separate docking runs. [S2 Table](#pone.0225244.s006){ref-type="supplementary-material"} provides raw data for docking results for panels A, B, C, and D. (E and F) *In vitro* conjugation capacity.](pone.0225244.g004){#pone.0225244.g004}

![Verification of the prediction of *in silico* conjugation capacities of UGT1A1 mutants.\
(A) *In silico* conjugation capacities (gray bars) for bilirubin were calculated by using molecular docking results and our mathematical model and were compared with reported *in vitro* conjugation capacities (black bars). (B) *In silico* and *in vitro* conjugation capacities of SN-38 were compared similarly, as done for bilirubin. (C) Pearson\'s correlation coefficient was used to analyze the correlation between *in silico* and *in vitro* conjugation capacities. \*, Calculated from *in vivo* conjugation capacity \[[@pone.0225244.ref005]\]. ND, not detected.](pone.0225244.g005){#pone.0225244.g005}

![Correlation analysis between *in silico* and *in vitro* conjugation capacities.\
Regression equation (solid line), Pearson\'s correlation coefficient (R), and P value are shown.](pone.0225244.g006){#pone.0225244.g006}

Discussion {#sec016}
==========

Adverse drug reactions and differences in drug efficacies are often caused by mutations in drug metabolizing agents, drug targets, and drug transporters \[[@pone.0225244.ref042]\]. Recently, novel mutations causing amino acid substitutions have been found by genome analysis with high-throughput sequence technology \[[@pone.0225244.ref043]\]. These mutations cause quantitative reductions and loss of function in the enzymes \[[@pone.0225244.ref044]\]. Drug efficacy differences and adverse drug reactions generally do not occur without major mutations and polymorphism in promoter regions. If novel mutants are found, genetic information is unknown, and therefore genetic analysis is not used in a clinical therapeutic setting.

In this research, we developed *in silico* procedures that consists of a mathematical model and molecular simulation analyses, and we evaluated its validity. We strictly selected and specified software for molecular simulation and parameter settings to mimic the conjugation process by UGT1A1, and the correctness of all modeled structures in this research was confirmed by the stable RMSD trajectory and low percentages in disallowed regions of Ramachandran plots.

To derive our mathematical model, we both performed docking analyses of UGT1A1 with the coenzyme or substrates (AAP and E2) and obtained the *in vitro* conjugation capacities of G71R, F83L. I322V, R336L, H376R, and P387S mutant of UGT1A1s. We compared *in silico* and *in vitro* results for two substrates to identify the key factors in this enzymatic reaction. We then found the number of hydroxyl orientations of substrate obtained from docking simulation analysis, which we identified as one feature ([Fig 2](#pone.0225244.g002){ref-type="fig"}, [Table 1](#pone.0225244.t001){ref-type="table"}) that we previously identified as being a key assumption \[[@pone.0225244.ref005]\]. In our docking analysis using the AutoDock program, similar docking results were acquired by the docking program of MOE software. Moreover, we found the same feature with other UGT1A enzymes: UGT1A7 and UGT1A10 ([S4 Fig](#pone.0225244.s004){ref-type="supplementary-material"}). These results suggest that the conjugation capacities of UGT1As are regulated by the number of hydroxyl orientations of the substrates. After our comparative analysis, we derived the mathematical model including the number of docking poses with correct binding, and it correctly determined the conjugation capacity of UGT1A1 mutants when conjugated with AAP and E2 ([Fig 3](#pone.0225244.g003){ref-type="fig"}).

Finally, our procedure *in silico*, which consists of molecular simulation analyses and our mathematical model, was validated by its use for the glucuronidation of bilirubin and SN-38. We compared the calculated conjugation capacities *in silico* with reported conjugation capacities *in vitro* \[[@pone.0225244.ref008], [@pone.0225244.ref038]--[@pone.0225244.ref041]\]. These predicted conjugation capacities closely approximated the reported *in vitro* findings ([Fig 5](#pone.0225244.g005){ref-type="fig"}). These results indicated that our mathematical model is valuable to predict the capacity of UGT1A1 to metabolize drugs. In this research, our procedure demonstrates the potential to predict the capacity of all UGT1A1 mutants based on [Fig 6](#pone.0225244.g006){ref-type="fig"}, which shows the data of the most studied mutants *in vitro*, and it also suggests that the same strategy may be available for other metabolic enzymes. This experimental procedure thus provides important information about adverse drug reactions for clinicians.

Supporting information {#sec017}
======================

###### Validation of the 3D structures of wild-type UGT1A1 and UGT1A1 mutants.

\(A\) The RMSD curves of the 10,000-ps trajectories for the backbone atoms of the UGT1A1 mutants were calculated with respect to the initial structures as a function of time. (B) Ramachandran plots for UGT1A1s. (C) Plot statistics for each UGT1A1.

(TIFF)

###### 

Click here for additional data file.

###### Cartoon representations of 3D structures of wild-type UGT1A1 and mutant UGT1A1s that we used in this study.

(TIFF)

###### 

Click here for additional data file.

###### LC-MS/MS analysis of AAPG and E2G.

Representative chromatograms of (A) AAPG and (B) E2G in the reaction mixtures include authentic standard AAPG and E2G, reaction mixtures without UGT1A1, and mixtures with wild-type UGT1A1 or G71R-mutant UGT1A1. AAPG and E2G were detected in the reaction mixtures with wild-type UGT1A1 and G71R-mutant UGT1A1, whereas glucuronides were absent in the reaction mixtures without UGT1A1.

(TIFF)

###### 

Click here for additional data file.

###### Comparison between docking results and reported *in vitro* conjugation capacities of UGT1A7 and UGT1A10.

(A and B) The number of correct binding modes of UDPGA per 100 separate docking runs. (C and D) The number of correct binding modes (hydroxyl orientations) of substrate per 100 separate docking runs. (E and F) Reported *in vitro* conjugation capacity. A correlation was shown between the hydroxyl orientation of the substrate and the *in vitro* conjugation capacity.

(TIFF)

###### 

Click here for additional data file.

###### Intermolecular hydrogen bond distance of VvGT and UDP in the crystal structure and the docking results.

(DOCX)

###### 

Click here for additional data file.

###### Docking results for UGT1A1 with UDPGA, AAP, E2, bilirubin, and SN-38.

(DOCX)

###### 

Click here for additional data file.

###### Variables and constants of the mathematical model.

(DOCX)

###### 

Click here for additional data file.

###### Analysis of the conformational difference between the docking model and the crystal structure.

(DOCX)

###### 

Click here for additional data file.

###### Correlation between docking simulation results and *in vitro* conjugation capacity of UGT1A7 and UGT1A10.

(DOCX)

###### 

Click here for additional data file.
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Additional Editor Comments:

Dear Dr. Takaoka,

Thank you for submitting to PLOS ONE. After careful review, I have decided that a major revision is required for your manuscript. You will find each reviewer\'s comments attached with this decision letter. It would be helpful to have all of these comments addressed if you decide to revise. As well, I am in strong agreement with Reviewer 1 that M/S traces are provided as supplementary for your data, including a new primary figure with example traces for the major reactions. As well, there needs to be much more clarification and detail with respect to the reaction methodology. Please also address any formatting issues identified by the reviewers, particularly, please provide clearer images for Figure 1. I\'m also in agreement with both reviewers that at times, the manuscript is difficult to read. Overall, the major points are very understandable, but some word choices or grammatical errors do make specific results harder to interpret. I would like to refer to Publication Guideline 5 from PLOS ONE:

\"If the language of a paper is difficult to understand or includes many errors, we may recommend that authors seek independent editorial help before submitting a revision. These services can be found on the web using search terms like "scientific editing service" or "manuscript editing service."

I recommend exploring these services so that the flow of the entire paper is more cohesive and the language a little more clear.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this paper, Takaoko et al attempt to validate a computer-based methodology to predict the efficacy of mutant UGT1A1 binding and activity to potential substrates. The data suggest that they have produced a nice model. However, there are many deficiencies in terms of the method description and overall manuscript layout and verbage that made the paper difficult to interpret.

Major issues:

1\. What was the normalizing control for transfection efficiency?

2\. How were the glucuronide peaks confirmed for all substrates?

3\. The authors should show representative LC-MS/MS runs for all assays.

4\. What was the sensitivity of all of their assays? Minimal level of detection? Variability? How many times were each experiment run? Etc.

5\. P. 10. Line 162. What SDM method was used?

6\. P. 11. Line 174. What is the 'UGT reaction mix'? This reviewer is not confident about the use of this procedure and it providing accurate results.

7\. Lines 182-184. Why were PNPG and EE2 added to the reaction mix?

8\. Too many supplemental tables and figures.

9\. Fig. S1 is not well-explained.

10\. Fig. S3 is not sufficiently clear.

11\. Table S1 is not properly formatted.

Lots of English to correct, including the following:

P. 4. Line 51. Fix 'UGT1A1s'. Change 'especially' to 'including'.

Line 53. reported 'on a' binding model.

Lines 69-70. 'sequence' to 'sequencing'.

Lines 76-77. Not great English.

Line 78. The word 'concretely' is not meaningful here.

Line 80. Change to 'We subsequently developed...'.

P.5. Line96. Delete 'by'.

P. 5. Line 99. Is solvate a word?

Line 111. Delete 'We can see that', and change 'is' to 'was'.

P.6. Line 116. Change ' following' to 'docking'

Line 119. Add 'The' at the beginning of the sentence.

Do not put figure legends within the text of the manuscript -- makes it difficult to read.

P. 10. Line 169. Delete the use of the term 'entry clone'. Just say that the vector was used to generate a clone....

Line 166. Poor sentence.

P. 11. Line 171. '...used for UGT1A1 activity and luciferase assays'.

P. 13. Line 207. Use 'We removed one of the UGT1A1 mutants...'

Line 215. Add 'and' L233R.

P. 14. Line 222. Finally, 'a'...

Line 234. You are comparing the conjugation capacity of UGT1A1 against AAP and E2 with...

Table 1. The UDPGA rows are repetitive and unnecessary. The amino acid changes headers are also repetitive and unnecessary.

Table 3. Should be a supplemental table as it does not provide data.

Table 4. The same should be followed for Table 4 as described above for Table 1. For Table 4, why were no data provided for N400D and W461R -- this should at least be explained in a footnote within the table.

P. 23. Line 348. You do not need this sentence.

Line 354. Poor sentence structure.

Line 359-60. Should be, 'In our docking analysis using the AutoDock...'.

Lines 362, 374, 541, 543, 545. Should read, 'UGT1A enzymes...'.

Line 364. Should read' 'including the number...'.

Lines 377-79. Don't need this sentence.

Reviewer \#2: The utility for this technology is exciting and results are encouraging. The introduction follows a logical line of reasoning for what the authors set out to accomplish and why it is important.

1\. It would be helpful to define \"molecular simulation" because it was challenging to determine whether it was synonymous with "in silico" throughout the paper.

2\. Line 54, please add "amino acids" before listing them so the reader knows what the list is.

3\. Line 98, please define TIP3P.

4\. Line 103, please define MM.

5\. I can't see the Figure 1 images. Please enhance and possibly enlarge.

6\. The location of the figure legends makes the text a little tougher to follow. It would be easier as a reviewer to have the figure legends at the end of the document with the figures. The first section of results is broken up by one figure legend and two tables, making it more work for the reader to figure out what the block of text is associated with.

7\. There are several inconsistencies relating to the figures. For instance, when referenced within the text in parentheses, most times it appears as (fig X) and at least once, it appears as (fig. X). There are also spaces between figure numbers and panel letter in places and not in others. In the figure legends, some are listed as Panels "A,B" and other times as (A), (B).

8\. It would be helpful for Table 1 and Figure 2 to be near each other so that they can be viewed together.

Figures 2 and 3 are showing the same data for acetaminophen and 17-B-estradiol in separate graphs and then in a single graph. The pattern is not repeated for the bilirubin and SN-38. I recommend the authors be consistent and either do both graphs for bilirubin and SN-38 as well or just show figure 3 for the acetaminophen and 17-B-estradiol.

9\. It would be helpful for the authors to add a small figure legend within the graphic that says what the grey and black bars are for figures 3 & 4. Also, a small figure legend within figure 5 listing each of the identities of the symbols and the r value and slope.

10\. I would like to see a citation for the sentence in lines 345-346. This may just be an oddly worded sentence since the text of the article is about mutations and polymorphisms that alter amino acids in the protein sequences; however, it should be either cited or altered.

11\. It would be more impactful if the authors stated in the results section which correlations were statistically significant. It may be that all correlations mentioned in the results were statistically significant, but it still makes it more work for the reader to figure that out.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225244.r002

Author response to Decision Letter 0

14 Oct 2019

Please see \'Response to Reviewers\'.

###### 

Submitted filename: reviewers_comments-and-answer.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0225244.r003

Decision Letter 1

Dluzen

Douglas

Academic Editor

© 2019 Douglas Dluzen

2019

Douglas Dluzen

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

28 Oct 2019

PONE-D-19-22725R1

Establishment of the experimental procedure for prediction of conjugation capacity in mutant UGT1A1

PLOS ONE

Dear Dr. Takaoka,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Dec 12 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.
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Additional Editor Comments (if provided):

Greetings Dr. Takaoka,

After careful review of your responses, I am submitting to you my decision that a minor revision is needed. I believe you have satisfactorily answered the reviewer\'s comments and provided the additional information required to address their concerns. I have included minor comments and clarifications needed after reading the revised manuscript incorporating your changes. Thank you for your patience and I hope you find my comments helpful. I look forward to seeing your response and final draft.

Editor\'s Comments:

Line 59: Please clarify the term \'newborn diseases\'. Do you mean diseases in newborns? Or new diseases?

Line 66: Please clarify the UGT1A1\*28 allele is the promoter.

Lines 72-74: Can you be more specific what is being conjugated for better clarify.

Lines 75-76: Can you be more specific what is being conjugated for better clarify.

Line 81: Please be more specific for what is being conjugated in this context.

Line 85: Are there previous models for this? If so, please provide references.

Line 163: Please define why this mutant was selected for Figure 1F. Is this just a represented graph or a different reason for looking at this particular variant.

Line 167: No paragraph indent needed.

Line 310: Please rewrite to clarify: :"S2 Table show the variables and constants of the mathematical model for the docking results for each UGT1A1 variant." or similar so that it is more clear.

Lines 334-335: This should be clarified to \"validated for each tested metabolite.\" And the paragraph indentation can be eliminated for the next sentence to create one paragraph.

Line 339-340: Figure 4 legend does not appear to have text outside of the title (assuming similar to text in figure 2 legend).

Line 348: There does not appear be text for Figure 6 outside of a title.

Line 360: Should be procedures, not procedure

Line 368: Should be clarified to say several categorized mutant UGT1A1s.

Line 385: Are these the only known UGT1A1 variants, or just the most studied? Please clarify. 

Table S1: Please add in guidelines to this table so that the values for the hydrogen bars and their mean A distance are easier to read/categorize for each category. 

Best,

Doug Dluzen
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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